The Technical AnalystExchange: TSX Industry: Biotechnology
Oncolytics Biotech Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.63% $1.600
America/New_York / 3 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 120.67 mill |
| EPS: | -0.410 |
| P/E: | -3.90 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 75.42 mill |
| Avg Daily Volume: | 0.0834 mill |
| RATING 2024-05-03 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.90 | sector: PE 21.44 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -3.90 | industry: PE -18.01 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.460 (-71.25%) $-1.140 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.506 - 1.694 ( +/- 5.88%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.600 (0.63% ) |
| Volume | 0.0332 mill |
| Avg. Vol. | 0.0834 mill |
| % of Avg. Vol | 39.74 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ONC.TO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ONC.TO
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.